Patient reported preferences for sleep interventions among women receiving buprenorphine for opioid use disorder

被引:2
|
作者
Eglovitch, Michelle [1 ]
Parlier-Ahmad, Anna Beth [1 ]
Legge, Catherine [2 ]
Chithranjan, Sajanee [2 ]
Kolli, Saisriya [2 ]
Violante, Stephanie [1 ]
Dzierzewski, Joseph M. [3 ]
Huhn, Andrew Stephen [4 ]
Wilkerson, Allison [5 ]
Martin, Caitlin Eileen [6 ,7 ]
机构
[1] Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA
[2] Virginia Commonwealth Univ, Sch Med, Richmond, VA USA
[3] Natl Sleep Fdn, Washington, DC USA
[4] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[5] Med Univ South Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA
[6] Virginia Commonwealth Univ, Inst Drug & Alcohol Studies, Richmond, VA USA
[7] Virginia Commonwealth Univ, Sch Med, Dept Obstet & Gynecol, Richmond, VA USA
来源
FRONTIERS IN PSYCHIATRY | 2023年 / 14卷
关键词
insomnia; sleep; buprenorphine; opioid use disorder; substance use disorder treatment; INSOMNIA; DISTURBANCE; METHADONE; ADULTS;
D O I
10.3389/fpsyt.2023.1244156
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
AimAmong individuals receiving medication for OUD (MOUD), insomnia is highly prevalent and increases the risk for negative OUD outcomes. However, little is known about MOUD patient-reported preferences for insomnia treatments among women with OUD. This mixed-methods study explored acceptability of and patient preferences for sleep interventions among women in OUD treatment.MethodsThis is an analysis from an ongoing cross-sectional survey and interview study investigating the relationship between sleep and OUD recovery. The parent study is actively enrolling non-pregnant women between 18-45 years stabilized on buprenorphine from an outpatient program. Participants complete measures including the Insomnia Severity Index (ISI), with scores of & GE;10 identifying clinically significant insomnia symptoms. A sub-sample who met this threshold completed semi-structured interviews. Descriptive statistics were generated for survey responses, and applied thematic analysis was used for interview data.ResultsParticipants selected for the qualitative interview (n = 11) highlighted prior positive and negative experiences with sleep treatments, challenges with employing non-pharmacological sleep strategies, and preferences for both medical and behavioral sleep interventions while in recovery. Women emphasized the need for flexibility of sleep therapy sessions to align with ongoing social determinants (e.g., caregiving responsibilities) as well as for sleep medications without sedating effects nor risk of dependency.ConclusionsMany women receiving MOUD have concomitant insomnia symptoms, and desire availability of both pharmacologic and behavioral sleep interventions within the OUD treatment setting. Qualitative findings underscore the need for evidence-based sleep interventions that account for the unique socioenvironmental factors that may impact strategy implementation in this population.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] VARIATION IN TREATMENT PERSISTENCE BETWEEN ACUTE AND CHRONIC OPIOID USERS RECEIVING BUPRENORPHINE PRODUCTS FOR OPIOID USE DISORDER
    Varisco, T.
    Thornton, J. D.
    VALUE IN HEALTH, 2020, 23 : S206 - S206
  • [42] Patient Satisfaction with Shared Medical Appointments Among Patients with Opioid Use Disorder Attending an Urban Buprenorphine Clinic
    Akyar, Serra
    Ruthberg, Stephanie
    Lao, Kristyn
    Nyaku, Amesika
    Zerbo, Erin
    AMERICAN JOURNAL ON ADDICTIONS, 2021, 30 (03): : 236 - 236
  • [43] Reported drug allergies among patients with opioid use disorder
    Li, Lily
    Price, Christin
    Suzuki, Joji
    Laidlaw, Tanya
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB160 - AB160
  • [44] Patient-Reported Goals of Youths in Canada Receiving Medication-Assisted Treatment for Opioid Use Disorder
    Chai, Darren
    Rosic, Tea
    Panesar, Balpreet
    Sanger, Nitika
    van Reekum, Emma A.
    Marsh, David C.
    Worster, Andrew
    Thabane, Lehana
    Samaan, Zainab
    JAMA NETWORK OPEN, 2021, 4 (08)
  • [45] The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder
    Joao P. De Aquino
    Suprit Parida
    Mehmet Sofuoglu
    Clinical Drug Investigation, 2021, 41 : 425 - 436
  • [46] The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder
    De Aquino, Joao P.
    Parida, Suprit
    Sofuoglu, Mehmet
    CLINICAL DRUG INVESTIGATION, 2021, 41 (05) : 425 - 436
  • [47] Buprenorphine Treatment for Opioid Use Disorder: An Overview
    Matisyahu Shulman
    Jonathan M. Wai
    Edward V. Nunes
    CNS Drugs, 2019, 33 : 567 - 580
  • [48] Buprenorphine Treatment for Opioid Use Disorder: An Overview
    Shulman, Matisyahu
    Wai, Jonathan M.
    Nunes, Edward V.
    CNS DRUGS, 2019, 33 (06) : 567 - 580
  • [49] Adherence to Buprenorphine Treatment in Opioid Use Disorder
    Williams, Ted D.
    Sumner, Michael
    Dixit, Shailja
    Urbaniak, Dennis
    AMERICAN JOURNAL ON ADDICTIONS, 2022, 31 (04): : 278 - 278
  • [50] Quality of buprenorphine care for opioid use disorder
    Anderson, Kelly E.
    Eckstein, Julia
    Chaisson, Christine E.
    Scholle, Sarah H.
    Niles, Lauren
    Dy, Sydney M.
    Saloner, Brendan
    Alexander, G. Caleb
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 199 - 200